- Home
- TBPH vs GHY Comparison
TBPH vs GHY Comparison
Compare TBPH & GHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- GHY
- Stock Information
- Founded
- TBPH 2013
- GHY 2012
- Country
- TBPH United States
- GHY United States
- Employees
- TBPH N/A
- GHY N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- GHY Trusts Except Educational Religious and Charitable
- Sector
- TBPH Health Care
- GHY Finance
- Exchange
- TBPH Nasdaq
- GHY Nasdaq
- Market Cap
- TBPH 485.8M
- GHY 527.9M
- IPO Year
- TBPH N/A
- GHY N/A
- Fundamental
- Price
- TBPH $9.59
- GHY $12.53
- Analyst Decision
- TBPH Buy
- GHY
- Analyst Count
- TBPH 4
- GHY 0
- Target Price
- TBPH $13.75
- GHY N/A
- AVG Volume (30 Days)
- TBPH 217.1K
- GHY 184.8K
- Earning Date
- TBPH 11-12-2024
- GHY 01-01-0001
- Dividend Yield
- TBPH N/A
- GHY 10.58%
- EPS Growth
- TBPH N/A
- GHY N/A
- EPS
- TBPH N/A
- GHY N/A
- Revenue
- TBPH $63,192,000.00
- GHY N/A
- Revenue This Year
- TBPH $11.41
- GHY N/A
- Revenue Next Year
- TBPH $37.36
- GHY N/A
- P/E Ratio
- TBPH N/A
- GHY N/A
- Revenue Growth
- TBPH 15.93
- GHY N/A
- 52 Week Low
- TBPH $7.44
- GHY $10.24
- 52 Week High
- TBPH $11.71
- GHY $11.92
- Technical
- Relative Strength Index (RSI)
- TBPH 50.13
- GHY 40.88
- Support Level
- TBPH $9.62
- GHY $12.42
- Resistance Level
- TBPH $10.08
- GHY $12.94
- Average True Range (ATR)
- TBPH 0.31
- GHY 0.14
- MACD
- TBPH -0.06
- GHY -0.05
- Stochastic Oscillator
- TBPH 25.00
- GHY 16.67
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.